Comparison of glucose monitoring between insulin glargine U-300 and insulin degludec in the elderly patients with type 2 diabetes mellitus

Comparison of glucose monitoring between insulin glargine U-300 and insulin degludec in the elderly patients with type 2 diabetes mellitus - Glucose monitoring in the elderly patients with type 2 diabetes mellitus using long-acting insulin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033779

Enrollment

Registered

2018-08-28

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Patients requiring insulin glargine U-300 for 7 days Patients requiring insulin degludec for 7 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 65 and older treating with basal oral therapy using insulin glargine or insulin degludec

Exclusion criteria

Exclusion criteria: 1. Patients who have diabetic ketosis or diabetic coma. 2. Patients with severe infection, severe injury or perioperative state. 3. Patients with severe diabetic complications such as neuropathy, retinopathy, and nephropathy. 4. Patients with severe hepatic, kidney, or cardiac diseases. 5. Pregnant. 6. Patients whom researchers rule out as inappropriate subjects.

Design outcomes

Primary

Measure	Time frame
Mean amplitude of glycemic excursion	—

Secondary

Measure	Time frame
Mean of daily difference, average blood glucose, standard deviation, hypoglycemia with glucose value less than 70 mg/dl	—

Countries

Japan

Contacts

Public ContactMasanao Fujii

Tsukuba University Hospital Mito Clinical Education and Training Center Mito Kyodo General Hospital Department of Endocrinology and Metabolism

mfujii1224@gmail.com029-231-2371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026